The CATNIP trial– a double blind randomized placebo controlled trial – tested whether treating cat allergy tested whether giving a monoclonal antibody called tezepelumab, which interferes with TSLP signaling, plus cat allergy shots to people with allergic rhinitis caused by cat allergens would safely provide better and longer-lasting s
The Immune Tolerance Network is currently requesting proposals for the supplementary mechanistic analyses for the remaining participant samples from the Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial.
The IMPACT trial – a double blind randomized placebo controlled study – was designed to test whether young, peanut allergic children (12-48 months) could be desensitized with peanut oral immunotherapy (OIT) and ultimately remain non-responsive to peanut after discontinuation of OIT.
The EXTEND trial was a double blind randomized placebo controlled study designed to test the effect of IL-6 receptor blockade (tocilizumab) in pediatric participants (age 6-17 years) with new onset type 1 diabetes. IL-6 pathway blockade is an effective immunotherapy in some autoimmune diseases including juvenile idiopathic arthritis and rheumatoid arthritis working, at
Christian P. Larsen, MD, DPhil, the Immune Tolerance Network’s (ITN’s) deputy director in transplantation, transplant surgeon, and immunologist was presented with the 2021 American Medical Association (AMA) Scientific Achievement Award.
The PAUSE trial was conducted to determine whether blocking CD28/B7 costimulatory signaling with abatacept would prevent relapse of psoriasis after effective treatment with ustekinumab (an IL12/23 antagonist).
In an article published today in Frontiers in Immunology, Immune Tolerance Network (ITN) leadership and clinical trial physicians review ITN's approach to the development of therapies that aim to establish tolerance in immune mediated diseases.
In a study published on April 22, 2020 in JACI, data from ITN’s CATEEC clinical trial was used to investigate the connection between asthma and allergic disease and the novel coronavirus, SARS-
The ITN article that reported the results of the CATEEC clinical trial, which compared clinical and biological responses to cat allergen exposure by nasal allergen challenge (NAC) or environmental exposure chamber (EEC) was selected to be an Editors’ Choice feature and was displayed on the American Academy of Allergy Asthma & Immunology (AAAAI) website.
The first patient first visit (FPFV) has occurred for ITN’s REBOOT clinical trial. REBOOT is a clinical study that aims to evaluate the safety and effectiveness of belimumab and intravenous rituximab at inducing remission of primary membranous nephropathy (MN) compared to rituximab alone.